The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Capita bumps up forecast for 2016 dividends, mid-caps to take Brexit hit

Mon, 18th Jul 2016 12:28

(ShareCast News) - The fall in sterling following Brexit would deliver an immediate boost to the value of companies' dividend payments but potential recessionary pressures would hit profits and dividends from UK-focused mid-caps hardest, Capita said in its second quarter 2016 Dividend Monitor. Despite that, the business process outsourcing company revised its headline dividend forecast for 2016 higher by 3.8% to £82.5bn, as a result of the 'windfall' from special dividends.UK dividend payouts rose by a record £28.8bn in the second quarter (Q2), marking a 7.6% rise in comparison to a year ago.That increase surpassed the previous record established in the first quarter of 2014, when Vodafone distributed a record payment in the wake of the sale of its stake in Verizon Wireless.However, the main reason for the jump in payouts was a flurry of special dividend payments - from a wide range of sectors - which more than quadrupled to £3.5bn.InterContinental Hotels led the way, paying out £1.0bn, followed by GlaxoSmithKline with another £970m.A total of 22 companies paid special dividends in the second quarter, the biggest number on record, although by value it was the third biggest total ever.Underlying dividends, on the other hand, decreased by 2.7% year-on-year to £25.2bn, despite a £960m gain in the value of dividends declared in US dollars and euros as the pound weakened ahead of the referendum vote.Very low levels of dividend coverDividends had held up much better than company profits over the last couple of years, Capita said, but that meant that dividend cover had fallen to very low levels."Inevitably, dividend growth is difficult to sustain in those circumstances, and this explains why the underlying picture is weak," it said.The financial sector was the largest payer in Q2, despite a cancellation from StanChart and a cut at Barclays. Life insurers and Lloyds were particularly strong.HSBC remained in the top spot in Q2, making up 10% of the total, while Lloyds Bank nudged into the top 5 for the first time since 2008.The top 5 dividend payers - HSBC, Barclays, Lloyds, BP and Royal Dutch Shell - made up 38% of the Q2 payouts, their biggest share since 2011.Dividends from mid-caps fell 5.5% to £3.6bn, albeit mainly reflecting changes to the index constituents."It's clear that mid-cap company dividends have continued to outpace their larger counterparts. For now at least," Capita said.Indeed, Capita forecast future dividends would take a hit from Brexit.Offsettinig that to an extent, Capita forecast that UK equities would yield 3.7% over the next twelve months, outpacing the 1.4% offered by cash savings accounts or the 3.4% on offer from UK property yields net of costs.Furthermore, Capita pointed out, for UK taxpayers the first £5,000 of dividend income was tax-free.
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.